CD69

Mouse IgG1, κ

Anti-µ stimulated human B lymphocytes

The FN50 monoclonal antibody specifically binds to human CD69. CD69 is also known as activation-induced molecule (AIM), early activation antigen (EA-1), very early activation antigen (VEA), C-type lectin domain family 2 member C (CLEC2C), MLR-3, GP32/28 and Leu-23. CD69 is a transmembrane type II homodimer receptor. CD69 is comprised of disulfide-linked, differentially glycosylated core protein subunits that are approximately 28 and 34 kDa in size. Each subunit contains a C-type lectin domain.  CD69 is expressed on activated T, B, and natural killer (NK) lymphocytes, thymocytes, neutrophils, eosinophils and platelets. In normal peripheral blood, a small and variable percentage of lymphocytes typically express detectable membrane CD69 antigen. Upon activation, CD69 antigen expression increases on lymphocytes. Peak CD69 expression generally occurs within 18 hours of activation, preceding the appearance of HLA-DR, IL-2Rα (CD25) and transferrin receptor (CD71). CD69 is highly expressed on the bright CD3+ subset of thymocytes. FN50 monoclonal antibody labels NK cells and most lymphocytes of the follicular mantle and perifollicular/interfollicular zone as well as germinal center T cells of lymph nodes and tonsils. Studies indicate that CD69 serves as a signaling receptor in the activation of a variety of cell types. Clone FN50 reacts with the human form of the 28/34 kDa dimeric glycoprotein expressed early during activation of lymphocytes, monocytes, and platelets. It also cross-reacts with a subset of peripheral blood mononuclear cells (lymphocytes and monocytes) of rhesus and cynomolgus macaque monkeys. The distribution on lymphocytes is similar to that observed with human peripheral blood lymphocytes with the majority of the cells demonstrating an increase in FN50 positivity following overnight incubation with phorbol myristrate acetate (PMA).

FN50 The FN50 monoclonal antibody specifically binds to human CD69. CD69 is also known as activation-induced molecule (AIM), early activation antigen (EA-1), very early activation antigen (VEA), C-type lectin domain family 2 member C (CLEC2C), MLR-3, GP32/28 and Leu-23. CD69 is a transmembrane type II homodimer receptor. CD69 is comprised of disulfide-linked, differentially glycosylated core protein subunits that are approximately 28 and 34 kDa in size. Each subunit contains a C-type lectin domain.  CD69 is expressed on activated T, B, and natural killer (NK) lymphocytes, thymocytes, neutrophils, eosinophils and platelets. In normal peripheral blood, a small and variable percentage of lymphocytes typically express detectable membrane CD69 antigen. Upon activation, CD69 antigen expression increases on lymphocytes. Peak CD69 expression generally occurs within 18 hours of activation, preceding the appearance of HLA-DR, IL-2Rα (CD25) and transferrin receptor (CD71). CD69 is highly expressed on the bright CD3+ subset of thymocytes. FN50 monoclonal antibody labels NK cells and most lymphocytes of the follicular mantle and perifollicular/interfollicular zone as well as germinal center T cells of lymph nodes and tonsils. Studies indicate that CD69 serves as a signaling receptor in the activation of a variety of cell types. Clone FN50 reacts with the human form of the 28/34 kDa dimeric glycoprotein expressed early during activation of lymphocytes, monocytes, and platelets. It also cross-reacts with a subset of peripheral blood mononuclear cells (lymphocytes and monocytes) of rhesus and cynomolgus macaque monkeys. The distribution on lymphocytes is similar to that observed with human peripheral blood lymphocytes with the majority of the cells demonstrating an increase in FN50 positivity following overnight incubation with phorbol myristrate acetate (PMA).

Mouse IgG1, κ

克隆 FN50 (also known as FN 50) (RUO)

Flow cytometry (Routinely Tested)

20 µl

Human (QC Testing), Rhesus, Cynomolgus, Baboon (Tested in Development)

CD69

AIM; CLEC2C; EA1; GP32/28; Leu23; MLR-3; VEA; BL-AC/P26

Aqueous buffered solution containing BSA and ≤0.09% sodium azide.

研发参考(2) 1. Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:1-1182. 2. Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995.

969